CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertiseCollaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected …
Jetzt den vollständigen Artikel lesen